Tnf Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Q/C Technologies, Inc. has filed an amendment to its 2025 Form 10-K to include previously omitted Part III information regarding directors, executive officers, compensation, and related matters.
Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) has filed a description of its capital stock, outlining authorized shares, common and preferred stock details, and the rights associated with each class.
TNF Pharmaceuticals provides a summary of its capital stock, including common and preferred shares, in its latest 10-K filing.
MyMD Pharmaceuticals' recent 10-K filing details its capital structure, including common and preferred stock, warrants, and potential anti-takeover provisions.